Nanoliposomal irinotecan (Nal-IRI)-based chemotherapy after irinotecan -based chemotherapy in patients with pancreas cancer

Smith Caleb J.; Bekaii-Saab Tanios S.; Cook Kathryn D.; Eiring Rachel A.; Halfdanarson Thorvardur R.; Hanna Mina; Jin Zhaohui; Jochum Jacob A.; Ma Wen Wee; Mitchell Jessica L.; Pitot Henry C.; Jatoi Aminah

首页> 外文期刊>Pancreatology: official journal of the International Association of Pancreatology (IAP) ... [et al.] >Nanoliposomal irinotecan (Nal-IRI)-based chemotherapy after irinotecan -based chemotherapy in patients with pancreas cancer

【24h】

Nanoliposomal irinotecan (Nal-IRI)-based chemotherapy after irinotecan -based chemotherapy in patients with pancreas cancer

机译：纳米脂素Irinotecan（NAL-IRI）在胰腺癌中基于胰腺癌的化疗后基于化疗

获取原文

获取原文并翻译 | 示例

获取外文期刊封面封底 >>

开具论文收录证明 >>

文献代查 >>

页面导航

摘要
著录项
相似文献
相关主题

摘要

Background: Nanoliposomal irinotecan (Nal-IRI) is a preferred second-line treatment for metastatic pancreas cancer. It is unclear, however, whether patients who had received irinotecan derive benefit.

机译：None

著录项

来源
《Pancreatology: official journal of the International Association of Pancreatology (IAP) ... [et al.]》 |2021年第2期|共5页
作者
Smith Caleb J.; Bekaii-Saab Tanios S.; Cook Kathryn D.; Eiring Rachel A.; Halfdanarson Thorvardur R.; Hanna Mina; Jin Zhaohui; Jochum Jacob A.; Ma Wen Wee; Mitchell Jessica L.; Pitot Henry C.; Jatoi Aminah;
展开▼
作者单位

Mayo Clin Dept Med 200 First St SW Rochester MN USA;

Mayo Clin Div Hematol Oncol 2779 E Mayo Blvd Phoenix AZ USA;

Mayo Clin Div Med Oncol 200 First St SW Rochester MN USA;

Mayo Clin Div Med Oncol 200 First St SW Rochester MN USA;

Mayo Clin Div Med Oncol 200 First St SW Rochester MN USA;

Mayo Clin Hlth Syst 404 W Fountain St Albert Lea MN USA;

Mayo Clin Div Med Oncol 200 First St SW Rochester MN USA;

Mayo Clin Div Med Oncol 200 First St SW Rochester MN USA;

Mayo Clin Div Med Oncol 200 First St SW Rochester MN USA;

Mayo Clin Div Med Oncol 200 First St SW Rochester MN USA;

Mayo Clin Div Med Oncol 200 First St SW Rochester MN USA;

Mayo Clin Div Med Oncol 200 First St SW Rochester MN USA;

展开▼
收录信息
原文格式 PDF
正文语种 eng
中图分类消化系及腹部疾病;
关键词
Pancreas cancer; Liposomal; Guidelines; Irinotecan; Survival;

机译：胰腺癌;脂质体;准则;IRINOTECAN;生存;

相似文献

外文文献
中文文献
专利

1. Efficacy of irinotecan-based chemotherapy after exposure to an anti-PD-1 antibody in patients with advanced esophageal squamous cell carcinoma [J] . Bo Zhang, Xi Wang, Qun Li, 中国癌症研究（英文版） . 2019,第006期
2. Chemotherapy with or without irinotecan in patients with advanced or recurrent gastric cancer: a meta-analysis of randomized controlled trials [J] . Zeng Chao, Zhou Hang, Wei Yang, 中华医学杂志（英文版） . 2014,第005期
3. Bimonthly chemotherapy with oxaliplatin, irinotecan, infusional 5-fluorouracil/folinic acid in patients with metastatic colorectal cancer pretreated with irinotecan- or oxaliplatin-based chemotherapy. [J] . Nobili S, Checcacci D, Filippelli F, Journal of chemotherapy . 2008,第5期

机译：对以伊立替康或奥沙利铂为基础的化疗预处理的转移性结直肠癌患者，每两月用奥沙利铂，伊立替康，输注5-氟尿嘧啶/亚叶酸进行化疗。
4. Phase II trial of cetuximab plus irinotecan for oxaliplatin- and irinotecan-based chemotherapy-refractory patients with advanced and/or metastatic colorectal cancer: Evaluation of efficacy and safety based on kras mutation status (T-CORE0801) [J] . SoedaH., ShimodairaH., GamohM., Oncology: International Journal of Cancer Research and Treatment . 2014,第1期

机译：西妥昔单抗联合伊立替康治疗以奥沙利铂和伊立替康为基础的难治性晚期和/或转移性结直肠癌患者的II期试验：基于kras突变状态评估疗效和安全性（T-CORE0801）
5. Phase II trial of cetuximab plus irinotecan for oxaliplatin- and irinotecan-based chemotherapy-refractory patients with advanced and/or metastatic colorectal cancer: Evaluation of efficacy and safety based on kras mutation status (T-CORE0801) [J] . SoedaH., ShimodairaH., GamohM., Oncology: International Journal of Cancer Research and Treatment . 2014,第1期

机译：西妥昔单抗的II期试验加上伊耳素和伊替替康的化疗 - 难治患者的先进和/或转移性结直肠癌：基于KRA突变状态的疗效和安全性评估（T-Core0801）
6. Efficacy of combination chemotherapy with docetaxel and irinotecan as first- or second-line treatment for advanced gastric cancer [C] . K. Sugiyama, A. Ishikawa, T. Watanabe International Gastric Cancer Congress . 2009

机译：组合化疗与多西紫杉醇和伊替康的疗效，作为晚期胃癌的第一或二线治疗
7. Subgroup analysis based on prognostic and predictive gene signatures for adjuvant chemotherapy in early-stage non-small-cell lung cancer patients [D] . Pluta, Dustin. 2015

机译：基于预后和预测基因特征的亚组分析用于早期非小细胞肺癌患者的辅助化疗
8. Oxaliplatin-based first-line chemotherapy is associated with improved overall survival compared to first-line treatment with irinotecan-based chemotherapy in patients with metastatic colorectal cancer – Results from a prospective cohort study [O] . Norbert Marschner, Dirk Arnold, Erik Engel, 2015

机译：与基于伊立替康的一线治疗相比基于奥沙利铂的一线化疗可改善转移性结直肠癌患者的总生存率–前瞻性队列研究结果
9. Oxaliplatin-based versus irinotecan-based hyperthermic intraperitoneal chemotherapy (HIPEC) in patients with peritoneal metastasis from appendiceal and colorectal cancer: a retrospective analysis [O] . 2014

机译：基于奥沙利铂与基于伊立替康的腹膜癌和结直肠癌腹膜转移患者的高温腹膜内化疗（HIPEC）：回顾性分析
10. Chemotherapy-Induced Cognitive Impairment: A Novel Prospective Study of the Cognitive Effects of Platinum Taxane-Based Chemotherapy in Ovarian Cancer Patients. [R] . Miller, R. 2016

机译：化疗引起的认知障碍：基于紫杉烷的化疗对卵巢癌患者认知影响的新前瞻性研究。

Nanoliposomal irinotecan (Nal-IRI)-based chemotherapy after irinotecan -based chemotherapy in patients with pancreas cancer

摘要

著录项

相似文献

相关主题

期刊订阅